Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chemotherapy/Avelumab Plus Radiotherapy to Primary Esophageal Tumor for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma: The Ave-CRT Study

NCT03800953 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT03800953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03800953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chemotherapy/Avelumab Plus Radiotherapy to Primary Esophageal Tumor for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma: The Ave-CRT Study
Lead sponsor
National Taiwan University Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
March 20, 2019
Completion date
December 31, 2023
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal tumor, metastatic esophageal squamous cell carcinoma